News

TCM Group A/S Posts Strong Q2 2024 Performance

TCM Group A/S Posts Strong Q2 2024 Performance

TCM Group A/S: Interim Report for Q2 2024

Interim report for Q2 2024 (April 1 - June 30)
(All figures in brackets refer to the same period in 2023 – AUBO Production A/S has been included in the figures since July 3, 2023)

Sales growth and improved earnings achieved despite a tough market environment.

CEO Torben Paulin:
“In the second quarter, our sales showed positive growth, even with the expected downturn in the B2B kitchen market. We experienced an organic sales increase of 5% year-on-year, bolstered by a remarkable over 25% growth in B2C sales. As anticipated, B2B sales saw a decline this quarter due to a slowdown in the Project sales sector. Overall, our revenue for Q2 reached DKK 332 million, up from DKK 256 million in the same quarter last year. In Denmark, which represents 80% of our Group revenue, sales grew by 15%, with an underlying organic growth rate of 6%.

Our overall gross margin improved to 21.5% in Q2, compared to 20.2% in the same quarter last year. This margin growth is attributed to the inclusion of AUBO sales (following the acquisition of AUBO Production in Q3 of 2023) and an increase in the proportion of higher-margin B2C sales.

In Q2, our adjusted EBIT was DKK 28 million, an increase from DKK 22 million in Q2 last year, with an adjusted EBIT margin of 8.4%, slightly down from 8.7% in Q2 last year. When factoring in the amortization of intangible assets from the AUBO acquisition, the underlying adjusted EBIT margin improved from 8.7% last year to 8.9% this year.

We reported a free cash flow of DKK 26 million, a significant rise from DKK -2 million last year, driven by higher earnings and a notable improvement in working capital. Our leverage ratio decreased to 3.20, down from 3.73 in the previous quarter, which remains comfortably within our agreed covenants.

During the second quarter, TCM Group expanded its footprint in Denmark by opening two additional AUBO branded stores.

In line with our commitment to transparency regarding the environmental impact of our products, we released third-party approved and validated Environmental Product Declarations (EPD) for the AUBO brand this quarter, ensuring that all our brands are now covered by EPDs.

We have revised our financial outlook for 2024, now anticipating full-year revenue between DKK 1,125-1,200 million (up from DKK 1,000-1,150 million) and adjusted EBIT earnings in the range of DKK 70-90 million (previously DKK 55-85 million). This updated outlook reflects an expected positive impact from the adjustment of the contingent consideration related to the AUBO Production A/S acquisition, estimated at DKK 3-5 million.

Financial Highlights for Q2 2024

  • Revenue of DKK 332.2 million (DKK 255.5 million), representing a 30.0% increase.
  • Adjusted EBITDA of DKK 36.7 million (DKK 27.5 million), with a margin of 11.1% (10.8%).
  • Adjusted EBIT of DKK 28.0 million (DKK 22.3 million), margin at 8.4% (8.7%).
  • Non-recurring items had a total impact of DKK 0.0 million (DKK 2.8 million).
  • EBIT of DKK 28.0 million (DKK 19.5 million), corresponding to a margin of 8.4% (7.6%).
  • Net profit of DKK 18.9 million (DKK 12.2 million).
  • Free cash flow was DKK 25.8 million (DKK -1.6 million).
  • Cash conversion ratio stood at 94.8% (48.8%).

Financial Highlights for H1 2024

  • Revenue of DKK 624.7 million (DKK 519.4 million), an increase of 20.3%.
  • Adjusted EBITDA of DKK 61.1 million (DKK 45.5 million), with a margin of 9.8% (8.8%).
  • Adjusted EBIT of DKK 43.8 million (DKK 35.4 million), margin at 7.0% (6.8%).
  • Non-recurring items had a negative impact of DKK 0.0 million (DKK 4.7 million).
  • EBIT of DKK 43.8 million (DKK 30.9 million), corresponding to a margin of 7.0% (5.9%).
  • Net profit of DKK 25.9 million (DKK 17.6 million).
  • Free cash flow was DKK 38.4 million (DKK -37.4 million).
  • Full-year guidance remains at revenue between DKK 1,125-1,200 million and adjusted EBIT earnings of DKK 70-90 million.

For more information, please contact:

Torben Paulin, CEO, TCM Group A/S, +45 21 21 04 64
Thomas Hjannung, CFO, TCM Group A/S, +45 25 17 42 33
IR Contact – ir@tcmgroup.dk

About TCM Group

TCM Group is the third-largest manufacturer of kitchens and bathroom furniture in Scandinavia. Our products are designed and produced in Denmark, reflecting a strong tradition of quality and craftsmanship. We operate a multi-brand strategy, with our primary brand being Svane Køkkenet, alongside Tvis Køkken, Nettoline, and AUBO. Together, these brands cover a wide pricing spectrum and are distributed through approximately 220 dealers across Denmark and Scandinavia. Additionally, we offer private label kitchens through DIY stores in Denmark and independent kitchen stores in Norway, and we supply the 45% owned e-commerce kitchen business Celebert, which operates under various brands.

Frequently Asked Questions

What does TCM Group A/S report for Q2 2024?

TCM Group A/S reported significant growth in sales and earnings, achieving a revenue of DKK 332 million despite market challenges.

How did the company's gross margin change in Q2 2024?

The overall gross margin rose to 21.5% in Q2 2024, up from 20.2% in the same period last year.

What is the financial outlook for TCM Group for 2024?

The financial outlook for 2024 anticipates revenue between DKK 1,125-1,200 million and adjusted EBIT earnings ranging from DKK 70-90 million.

Which brands does TCM Group operate under?

TCM Group operates several brands, including Svane Køkkenet, Tvis Køkken, Nettoline, and AUBO.

How did the free cash flow perform in Q2 2024?

In Q2 2024, free cash flow reached DKK 26 million, a notable increase compared to DKK -2 million last year.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading